884497-46-5

Basic information

• Product Name: Methyl 3-aMino-5-fluorobenzoate
• Synonyms: Methyl 3-aMino-5-fluorobenzoate;Benzoic acid, 3-aMino-5-fluoro-, Methyl ester;3-Amino-5-fluorobenzoic acid methyl ester;3-amino-5-fluorobenzoate methyl
• CAS NO: 884497-46-5
• Molecular Formula: C₈H₈FNO₂
• Molecular Weight: 169.1530232
• Mol File: 884497-46-5.mol

Chemical Properties

• Boiling Point: 296.6±25.0 °C(Predicted)
• Appearance: White to yellow/Solid
• Density: 1.264±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 2.44±0.10(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: Methyl 3-aMino-5-fluorobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-aMino-5-fluorobenzoate(884497-46-5)
• EPA Substance Registry System: Methyl 3-aMino-5-fluorobenzoate(884497-46-5)

Safety Data

• Hazardous Substances Data: 884497-46-5(Hazardous Substances Data)

Usage

Uses

Methyl 3-amino-5-fluorobenzoate is an amino acid widely used in pharmaceuticals and foods.

Upstream product

• 67-56-1 methanol 
• 786616-54-4 3-amino-5-fluorobenzoic acid 
• 14027-75-9 3-nitro-5-fluorobenzoic acid 
• 883987-72-2 methyl 3-fluoro-5-nitrobenzoate 
• 1342063-52-8 methyl 3-amino-2-bromo-5-fluorobenzoate 
• 328547-12-2 methyl 2-bromo-5-fluoro-3-nitrobenzoate 
• 1055331-73-1 2-bromo-5-fluoro-3-nitrobenzoic acid 
• 394-28-5 2-Bromo-5-fluorobenzoic acid 

Downstream Products

• 1244643-80-8 C₃₁H₂₈F₃N₇O₃S₂ 
• 1351161-89-1 C₁₈H₁₁ClF₃N₃O₃S 
• 1351161-97-1 C₂₂H₁₆ClF₃N₄O₂S₂ 
• 1351161-80-2 C₁₄H₁₀F₃NO₄S 
• 1343460-15-0 7-fluoro-3,3-dimethyl-2-(3-morpholin-4-yl-phenyl)-1,2,3,4-tetrahydro-quinoline-5-carboxylic acid 
• 1343460-31-0 N-[7-fluoro-3,3-dimethyl-2-(3-morpholin-4-yl-phenyl)-1,2,3,4-tetrahydro-quinoline-5-carbonyl]-methanesulfonamide 
• 1343460-52-5 cyclopropanesulfonic acid [7-fluoro-3,3-dimethyl-2-(3-morpholin-4-yl-phenyl)-1,2,3,4-tetrahydro-quinoline-5-carbonyl]-amide 
• 1343460-22-9 2-(3-bromo-phenyl)-7-fluoro-4-hydroxy-3,3-dimethyl-1,2,3,4-tetrahydro-quinoline-5-carboxylic acid methyl ester 
• 1343460-25-2 2-(3-bromo-phenyl)-7-fluoro-3,3-dimethyl-1,2,3,4-tetrahydro-quinoline-5-carboxylic acid methyl ester 
• 1343460-28-5 7-fluoro-3,3-dimethyl-2-(3-morpholin-4-yl-phenyl)-1,2,3,4-tetrahydro-quinoline-5-carboxylic acid methyl ester 
• 1343460-19-4 3-[(3-bromo-benzylidene)-amino]-5-fluoro-benzoic acid methyl ester 
• 1448347-96-3 2-(3-amino-5-fluorophenyl)propan-2-ol 
• 1448347-95-2 2-(3-(dibenzylamino)-5-fluorophenyl)propan-2-ol 
• 1448347-94-1 Methyl 3-(dibenzylamino)-5-fluorobenzoate 

Relevant articles and documents

From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4)

The mitogen-activated protein kinase (MAP) kinase 4 (MKK4) was found to be a major regulator of liver regeneration and could be a valuable drug target addressing liver related diseases by restoring its intrinsic regenerative capacity. We report on the synthesis and optimization of novel MKK4 inhibitors following a target-hopping strategy from the FDA-approved BRAFV600E inhibitor PLX4032 (8). Applying an iterative multi-parameter optimization process we carved out essential structural features yielding in compounds with a low nanomolar affinity for MKK4 and excellent selectivity profiles against the main off-targets MKK7 and JNK1, which, upon relevant inhibition, would totally abrogate the pro-regenerative effect of MKK4 inhibition, as well as against the off-targets MAP4K5, ZAK and BRAF with selectivity factors ranging from 40 to 430 for our best-balanced compounds 70 and 73.

ΒETA-CATENIN AND B-CELL LYMPHOMA 9 (BCL9) INHIBITORS

Disclosed are inhibitors for the β-catenin/BCL9 interaction. The inhibitors are selective for β-catenin/BCL9 over β-catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

FUSED TETRA OR PENTA-CYCLIC PYRIDOPHTHALAZINONES AS PARP INHIBITORS

Provided are certain fused tetra or penta-cyclic compounds and salts thereof, compositions thereof, and methods of use thereof.

Aminoheteroaryl benzamides as kinase inhibitors

The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

FUSED TETRA OR PENTA-CYCLIC PYRIDOPHTHALAZINONES AS PARP INHIBITORS

Provided are certain fused tetra or penta-cyclic compounds and salts thereof, compositions thereof, and methods of use thereof.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF

Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.

FUSED TETRA OR PENTA-CYCLIC PYRIDOPHTHALAZINONES AS PARP INHIBITORS

Provided are certain fused tetra or penta-cyclic compounds and salts thereof, compositions thereof, and methods of use thereof.

THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.